Oak Associates Ltd. OH Acquires 19,025 Shares of Pfizer Inc. $PFE

Oak Associates Ltd. OH grew its holdings in Pfizer Inc. (NYSE:PFE) by 4.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 426,707 shares of the biopharmaceutical company’s stock after buying an additional 19,025 shares during the quarter. Oak Associates Ltd. OH’s holdings in Pfizer were worth $10,343,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the first quarter worth about $27,000. Curio Wealth LLC grew its stake in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in shares of Pfizer in the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. bought a new position in Pfizer in the 2nd quarter worth approximately $29,000. Finally, Evelyn Partners Asset Management Ltd bought a new position in Pfizer in the 2nd quarter worth approximately $33,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Morgan Stanley decreased their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a research report on Wednesday, November 5th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.39.

Pfizer Trading Up 0.9%

NYSE PFE opened at $25.26 on Tuesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The stock has a 50-day simple moving average of $24.87 and a 200 day simple moving average of $24.51. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $143.61 billion, a PE ratio of 13.44, a P/E/G ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.